Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
CVAY736A2202
Autoimmune Disease Phase II
- 8.2 weeks
CYTB323R12101
Progressive Multiple Sclerosis (PMS) Phase I/II
- 11.8 weeks
- 1st site activated in Canada, 2nd site activated worldwide, Canada FPI and 3rd patient enrolled worldwide
DRI17476 (Fabulinus)
Type 1 Diabetes Phase II
- 12.4 weeks
- 3rd site activated worldwide
DRI17476 (Fabulinus)
Type 1 Diabetes Phase II
- 10.2 weeks
EFC14771
Uncontrolled Asthma Phase III
- 21.2 weeks
EFC17236 (MOBILIZE)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase III
- 8 weeks
- 1st site activated in Canada
EFC17504
Multiple Sclerosis Phase III
- 8.8 weeks
- 1st site activated in Canada
EFC17504
Multiple Sclerosis Phase III
- 9.8 weeks
- Canadian FPI
EFC17504
Multiple Sclerosis Phase III
- 8.6 weeks
EFC17919
Multiple Sclerosis Phase III
- 9 weeks
- 1st site activated in Canada
EFC17919
Multiple Sclerosis Phase III
- 10.8 weeks
- 2nd site activated in Canada
FRONTIERS
Cardiology Phase II
- 12.4 weeks
- 1st site activated in Canada
FRONTIERS
Cardiology Phase II
- 11.8 weeks
- 2nd site activated in Canada
FRONTIERS
Cardiology Phase II
- 17 weeks
INSIGHT
HIV-1 Phase II
- 9.4 weeks
- Co-2nd site activated in Canada - Co-7th site activated worldwide and Canadian FPI - 2nd patient enrolled globally
INSIGHT
HIV-1 Phase II
- 7.6 weeks
- Co-2nd site activated in Canada - Co-7th site activated worldwide
JADE
Head and Neck Cancer Phase III
- 13.4 weeks
- 1st site activated in Canada and 5th site activated worldwide
SOHO 22615
Non-Small Cell Lung Cancer (NSCLC) Phase III
- 12.6 weeks
- 1st site activated in Canada
TED18162
Multiple Myeloma Phase I/II
- 8.8 weeks
- 1st site activated in Canada and 2nd site activated worldwide
TED18162
Multiple Myeloma Phase I/II
- 18.8 weeks